SciSparc (SPRC) Competitors

$4.27 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$4.51 +0.24 (+5.71%)

As of 05/22/2026 07:15 PM Eastern

SPRC vs. APRE, BIVI, CALC, MTVA, and IMNN

Should you buy SciSparc stock or one of its competitors? MarketBeat compares SciSparc with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SciSparc include Aprea Therapeutics (APRE), BioVie (BIVI), CalciMedica (CALC), MetaVia (MTVA), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry.

How does SciSparc compare to Aprea Therapeutics?

SciSparc (NASDAQ:SPRC) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, SciSparc had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 1 mentions for SciSparc and 0 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.00 beat SciSparc's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
SciSparc	Neutral
Aprea Therapeutics	Positive

SciSparc has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. SciSparc's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 328.07%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

SciSparc has higher revenue and earnings than Aprea Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	2.83	-$12.18M	N/A	N/A
Aprea Therapeutics	$290K	40.56	-$12.60M	-$1.54	N/A

SciSparc has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

25.1% of SciSparc shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

SciSparc and Aprea Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does SciSparc compare to BioVie?

BioVie (NASDAQ:BIVI) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

SciSparc has higher revenue and earnings than BioVie.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
SciSparc	$860K	2.83	-$12.18M	N/A	N/A

BioVie has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market.

4.6% of BioVie shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 0.9% of BioVie shares are owned by company insiders. Comparatively, 1.5% of SciSparc shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, BioVie had 1 more articles in the media than SciSparc. MarketBeat recorded 2 mentions for BioVie and 1 mentions for SciSparc. BioVie's average media sentiment score of 0.40 beat SciSparc's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SciSparc	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SciSparc's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
SciSparc	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

SciSparc beats BioVie on 7 of the 9 factors compared between the two stocks.

How does SciSparc compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

25.1% of SciSparc shares are held by institutional investors. 41.6% of CalciMedica shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SciSparc's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
SciSparc	N/A	N/A	N/A

SciSparc has higher revenue and earnings than CalciMedica.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
SciSparc	$860K	2.83	-$12.18M	N/A	N/A

CalciMedica has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market.

In the previous week, CalciMedica had 3 more articles in the media than SciSparc. MarketBeat recorded 4 mentions for CalciMedica and 1 mentions for SciSparc. CalciMedica's average media sentiment score of 0.40 beat SciSparc's score of 0.00 indicating that CalciMedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SciSparc	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CalciMedica presently has a consensus price target of $10.00, indicating a potential upside of 1,490.08%. Given CalciMedica's stronger consensus rating and higher possible upside, research analysts plainly believe CalciMedica is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CalciMedica and SciSparc tied by winning 6 of the 12 factors compared between the two stocks.

How does SciSparc compare to MetaVia?

SciSparc (NASDAQ:SPRC) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

SciSparc's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
MetaVia	N/A	-172.92%	-89.39%

SciSparc has higher revenue and earnings than MetaVia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	2.83	-$12.18M	N/A	N/A
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 0.8% of MetaVia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MetaVia has a consensus target price of $20.00, suggesting a potential upside of 419.48%. Given MetaVia's stronger consensus rating and higher possible upside, analysts plainly believe MetaVia is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SciSparc has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market. Comparatively, MetaVia has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

In the previous week, MetaVia had 12 more articles in the media than SciSparc. MarketBeat recorded 13 mentions for MetaVia and 1 mentions for SciSparc. SciSparc's average media sentiment score of 0.00 beat MetaVia's score of -0.27 indicating that SciSparc is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SciSparc	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MetaVia	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SciSparc beats MetaVia on 8 of the 12 factors compared between the two stocks.

How does SciSparc compare to Imunon?

Imunon (NASDAQ:IMNN) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Imunon has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, SciSparc has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market.

SciSparc has higher revenue and earnings than Imunon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A
SciSparc	$860K	2.83	-$12.18M	N/A	N/A

In the previous week, Imunon had 6 more articles in the media than SciSparc. MarketBeat recorded 7 mentions for Imunon and 1 mentions for SciSparc. Imunon's average media sentiment score of 0.38 beat SciSparc's score of 0.00 indicating that Imunon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
SciSparc	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Imunon currently has a consensus price target of $10.00, indicating a potential upside of 354.55%. Given Imunon's stronger consensus rating and higher probable upside, research analysts plainly believe Imunon is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

4.5% of Imunon shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 2.8% of Imunon shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

SciSparc's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-341.23%	-153.79%
SciSparc	N/A	N/A	N/A

Summary

Imunon and SciSparc tied by winning 6 of the 12 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRC vs. The Competition

Export

Metric	SciSparc	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.41M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	N/A	17.79	21.22	25.66
Price / Sales	2.83	336.21	562.28	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	0.33	5.86	10.31	7.14
Net Income	-$12.18M	$74.99M	$3.57B	$335.98M
7 Day Performance	-6.15%	3.11%	6.43%	4.15%
1 Month Performance	-36.17%	-3.05%	3.57%	2.54%
1 Year Performance	-92.65%	34.38%	34.07%	35.06%

SciSparc Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRC SciSparc	0.0933 of 5 stars	$4.27 flat	N/A	-92.7%	$2.41M	$860K	N/A	4
APRE Aprea Therapeutics	4.2513 of 5 stars	$0.90 +12.5%	$4.07 +351.9%	-43.1%	$9.91M	$290K	N/A	7	Positive News Gap Down
BIVI BioVie	0.7073 of 5 stars	$1.35 +3.1%	N/A	-85.2%	$9.88M	N/A	N/A	10	Gap Down
CALC CalciMedica	2.6696 of 5 stars	$0.65 +4.5%	$10.00 +1,450.4%	-65.1%	$9.75M	N/A	N/A	30
MTVA MetaVia	1.8228 of 5 stars	$2.89 +53.7%	$20.00 +592.0%	-55.7%	$9.71M	N/A	N/A	8	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRC) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SciSparc (SPRC) Competitors

SPRC vs. APRE, BIVI, CALC, MTVA, and IMNN

How does SciSparc compare to Aprea Therapeutics?

Summary

How does SciSparc compare to BioVie?

Summary

How does SciSparc compare to CalciMedica?

Summary

How does SciSparc compare to MetaVia?

Summary

How does SciSparc compare to Imunon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SciSparc (SPRC) Competitors

SPRC vs. APRE, BIVI, CALC, MTVA, and IMNN

How does SciSparc compare to Aprea Therapeutics?

Does the media favor SPRC or APRE?

Is SPRC or APRE more profitable?

Do analysts prefer SPRC or APRE?

Which has stronger valuation and earnings, SPRC or APRE?

Which has more volatility and risk, SPRC or APRE?

Do institutionals and insiders have more ownership in SPRC or APRE?

Summary

How does SciSparc compare to BioVie?

Which has higher earnings and valuation, BIVI or SPRC?

Which has more risk and volatility, BIVI or SPRC?

Do insiders and institutionals hold more shares of BIVI or SPRC?

Does the media refer more to BIVI or SPRC?

Is BIVI or SPRC more profitable?

Do analysts recommend BIVI or SPRC?

Summary

How does SciSparc compare to CalciMedica?

Do institutionals and insiders believe in CALC or SPRC?

Is CALC or SPRC more profitable?

Which has preferable earnings and valuation, CALC or SPRC?

Which has more risk & volatility, CALC or SPRC?

Does the media refer more to CALC or SPRC?

Do analysts recommend CALC or SPRC?

Summary

How does SciSparc compare to MetaVia?

Is SPRC or MTVA more profitable?

Which has better earnings and valuation, SPRC or MTVA?

Do institutionals & insiders hold more shares of SPRC or MTVA?

Do analysts recommend SPRC or MTVA?

Which has more risk and volatility, SPRC or MTVA?

Does the media refer more to SPRC or MTVA?

Summary

How does SciSparc compare to Imunon?

Which has more volatility and risk, IMNN or SPRC?

Which has stronger valuation and earnings, IMNN or SPRC?

Does the media favor IMNN or SPRC?

Do analysts recommend IMNN or SPRC?

Do insiders & institutionals believe in IMNN or SPRC?

Is IMNN or SPRC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools